Eisai: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency
TOKYO and CAMBRIDGE, Mass […]
Tag: eisai
Eisai Commences Business Activities at New Pharma Sales Subsidiary in Israel
TOKYO, Jan 19, 2023 ̵ […]
Eisai to Divest Rights for Muscle Relaxant Myonal, Vertigo, and Equilibrium Disturbance Treatment Merislon in Asia to DKSH
TOKYO, Nov 7, 2022 – […]
Eisai Completes Construction of Its New Injection/Research Building at Kawashima Industrial Park in Japan
TOKYO, Oct 4, 2022 – […]
Eisai and Lifenet Enter Into Capital and Business Alliance Agreement Aimed at Building Ecosystem to Reduce Burden of Medical and Nursing Care
TOKYO, Aug 9, 2022 – […]
Eisai to Present at The Alzheimer’s Association International Conference (AAIC) 2022
TOKYO, Jul 26, 2022 ̵ […]
Eisai Announces Acquisition of Arteryex Shares (Making Arteryex a Subsidiary) to Strengthen and Rapidly Expand the Foundation of its Digital Solution Business
TOKYO, Apr 1, 2022 – […]
Eisai: Economic Arrangements of Amendment to Alzheimer’s Disease Treatment Collaboration Agreement with Biogen
TOKYO, Mar 15, 2022 ̵ […]
Biogen and Eisai Amend Collaboration Agreements on Alzheimer’s Disease Treatments
CAMBRIDGE, Mass., and TOK […]
Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator
TOKYO, Jan 6, 2022 – […]
Eisai and Digital Garage, Inc. Jointly Launch “Onlab Bio Dementia (Open Network Lab BioHealth Dementia Innovation Challenge)”
TOKYO, Nov 4, 2021 – […]
Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad in Five ASEAN Countries
TOKYO, Aug 31, 2021 ̵ […]
Eisai, Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai’s MORAb-202 Antibody Drug Conjugate
Tokyo and New York, Jun 1 […]
Eisai to Divest Rights for Zonegran in Europe and Other Regions to Advanz Pharma
TOKYO, Jun 15, 2021 ̵ […]
Eisai’s Statement of Commitment for Carbon Neutrality by 2040
TOKYO, May 11, 2021 ̵ […]
KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries
TOKYO, Mar 31, 2021 ̵ […]
